• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » 2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

VaccinewithNeedle-360x240.png
January 25, 2021
Suz Redfearn

Trials of COVID-19 vaccines, along with research into variants of the SARS-CoV-2 virus that causes the disease, will dominate the vaccine development space through 2022, with some nonCOVID vaccine trials slowly trickling back after being delayed by the pandemic.

COVID-19 research will still be around for at least the next two years, predicts Angela Branche, assistant professor at the University of Rochester Medical Center. In addition to studying COVID variants as they crop up and developing new vaccination approaches — such as Moderna’s current third “booster shot” trial — scores of postmarket studies will be needed.

In the meantime, vaccine makers have their hands full. There are more than 60 COVID-19 vaccine candidates in clinical trials and more than 85 in preclinical development. Another 260 vaccines are in the works, although many are delayed while COVID-19 remains such a high priority, say trial professionals. Those include vaccine candidates for respiratory syncytial virus (RSV), influenza, pneumococcal, Norovirus, Group B strep, MRSA, HIV and tick-borne diseases.

“I don’t know if there have ever been so many vaccines being developed at the same time for the same disease,” said Chris Doyle, director of Institutional Biosafety Committee Services for WCG IRB. “It’s crazy.”

Sponsors are also starting to test their vaccine candidates’ efficacy and safety in pediatric populations as well as in pregnant women. Building on the success of its mRNA vaccine in adults, Pfizer says it has been enrolling participants as young as age 12 in its phase 3 trial. Results are due later this year. And the drugmaker also has undertaken reproductive and developmental toxicity studies to determine the vaccine’s effect on the maternal population. It is not yet known when pregnant women may be able to start receiving the COVID vaccines.

Then there are the mutations in the virus. “It’s just a matter of time before that requires a change in the vaccines,” says Cynthia Dukes, vaccine industry veteran and chief business officer of Benchmark Research, a Texas-based network of clinical research sites. “If a whole new vaccine is needed, new studies will be needed,” says Dukes, adding that Benchmark tripled its staff in 2020 to keep up with demand.

Doyle warned, though, that COVID-19 vaccine candidates coming into human trials after Pfizer’s and Moderna’s vaccines have already become available may find recruiting tricky. “Who’s going to sign up to possibly get a placebo when you could — at some point in the near future — go to CVS and get a vaccine that you know works? It’s going to be a tough sell,” he said.

“Excitement and funding will drive a surge in mRNA vaccine research over the next several years, particularly in the infectious disease and cancer fields,” said Doyle. “They’re simple, adaptable, scalable, safe and can clearly be effective.”

Unfortunately, in their first wave, mRNA vaccines have been tough to handle. Researchers working on an expected second wave of mRNA-based vaccines for various ailments can now spend more time in phase 2 trials altering the antigens so they don’t need to be kept so cold, which has been a logistical challenge for the deployment of Pfizer’s and Moderna’s vaccines.

“They are very fragile vaccines,” said Dukes. “Researchers should be able to now find a way to optimize the vaccine so they can be stored, distributed and given more easily. Typically, we spend more time in phase 2 figuring out how to optimize a vaccine or improve its stability by tweaking the formulation, adjusting the manufacturing process. With COVID, we didn’t have the luxury to take all that time fine-tuning.”

Regardless, the success of the mRNA technology will ripple throughout the vaccine industry, experts say. Dukes said that vaccines that teams had been working on for many years are beginning to restart their trials after COVID-19 knocked most regular research off-track, and researchers may be able to take advantage of the new technologies now infusing the space. The suspended trials include vaccines to ward against strep A and soft-tissue infections.

The huge focus COVID-19 vaccine development got this year also brought needed attention to other vaccines in development, said Andy Lee, senior vice president and head of global clinical trial operations at Merck Research Labs. Those include Zika, Dengue, cytomegalovirus, RSV, porcine circovirus and Chikungunya.

The FDA announced in January that it would conduct accelerated review of Merck’s 15-strain flu shot with a target action date of July 18. The European Medicines Agency is also reviewing the application for the candidate.

But vaccines for infectious diseases that aren’t COVID may have a tough time recruiting in this season — and not just because there are so many COVID-19 vaccines to study. Said Dukes, “There had been a number of RSV and influenza trials, but because of social distancing and masking, we’re not seeing much disease.”

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing